Department of Medical Education, Miller School of Medicine, University of Miami, Miami, FL 33101, United States.
Department of Paediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, 46003, Spain.
Sex Med Rev. 2023 Dec 23;12(1):3-13. doi: 10.1093/sxmrev/qead020.
Preventative surgical procedures for patients who are breast cancer (BRCA) positive-namely, bilateral salpingo-oophorectomy and mastectomy-have been linked to changes in sexual function, including surgically induced menopause. A patient's decision to undergo preventive surgery as opposed to high-risk screening is heavily reliant on advice received from one's health care provider. Quality of life should be considered when shared decision making is conducted with patients.
To assemble and analyze findings related to patient-reported sexual function after these surgical procedures, to see if and how either procedure affects sexual function from patient baseline, and to determine whether the effects can be mitigated with menopausal hormone therapy.
A literature review based on the PubMed, Embase, and MEDLINE databases was conducted from inception through January 25, 2022. To be included, studies had to meet an a priori list of Medical Subject Headings: "BRCA" AND "sexual dysfunction" OR "dyspareunia." GRADE criteria were used to determine the quality of studies relating to menopause hormone therapy.
The search yielded 14 results, and 11 reported sufficient data for systematic review. Sexual function was measured via validated and investigator-generated surveys. All studies, no matter the survey metric, found significant reduction in sexual function with bilateral salpingo-oophorectomy; no studies revealed sexual function changes associated with mastectomy postsurgery. Few studies indicated that menopause hormone therapy resulted in significant improvement in sexual function, and all studies reported that postoperative sexual function could not reach baseline levels with therapy. No studies were high quality by GRADE metrics.
Prophylactic mastectomies and bilateral salpingo-oophorectomies among patients who are BRCA positive cause SF changes postprocedure. Menopausal hormone therapy offers little help in mediating symptoms. Significantly more research is needed to explore potential changes in sexual function, as it is an important aspect of quality of life for patients with BRCA positivity.
对于乳腺癌(BRCA)阳性患者,预防性手术(即双侧输卵管卵巢切除术和乳房切除术)与性功能变化相关,包括手术诱导的绝经。患者是否选择预防性手术而不是高危筛查,很大程度上取决于从医疗保健提供者那里获得的建议。在与患者进行共同决策时,应考虑生活质量。
汇总和分析这些手术后患者报告的性功能相关发现,以了解这两种手术是否以及如何影响患者基线时的性功能,并确定是否可以使用绝经激素治疗来减轻这些影响。
根据 PubMed、Embase 和 MEDLINE 数据库,从成立到 2022 年 1 月 25 日进行了文献回顾。为了被纳入,研究必须满足预先确定的医学主题词列表:“BRCA”和“性功能障碍”或“性交困难”。使用 GRADE 标准来确定与绝经激素治疗相关的研究质量。
搜索结果为 14 项,其中 11 项报告了足够的系统评价数据。性功能通过经过验证和研究者生成的调查进行测量。所有研究,无论调查指标如何,都发现双侧输卵管卵巢切除术会导致性功能显著下降;没有研究发现乳房切除术术后性功能发生变化。少数研究表明,绝经激素治疗可显著改善性功能,所有研究报告称,术后性功能无法通过治疗恢复到基线水平。没有研究达到 GRADE 标准的高质量水平。
BRCA 阳性患者的预防性乳房切除术和双侧输卵管卵巢切除术会导致术后 SF 改变。绝经激素治疗在缓解症状方面帮助不大。需要进行更多研究来探索性功能的潜在变化,因为这是 BRCA 阳性患者生活质量的一个重要方面。